Paraoxonase 1 in neurological disorders

Redox Report

Volumn 19, Issue 2, 2014, Pages 49-58

  Menini, Teresita ^a   Gugliucci, Alejandro ^a  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Cardiovascular risk; High density lipoprotein; Ischemic stroke; Oxidative stress; Parkinson's disease; PON1

Indexed keywords

ALZHEIMER'S DISEASE; CARDIOVASCULAR RISK; HIGH-DENSITY LIPOPROTEIN; ISCHEMIC STROKE; OXIDATIVE STRESS; PARKINSON'S DISEASE; PON1;

ALZHEIMER DISEASE; ANIMALS; ARYLDIALKYLPHOSPHATASE; GENOTYPE; HUMANS; LIPOPROTEINS, HDL; NERVOUS SYSTEM DISEASES; OXIDATIVE STRESS; STROKE;

EID: 84894294638     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000213Y.0000000071     Document Type: Review

References (122)

1. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57-60.
2. Aviram M, Vaya J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr Opin Lipidol 2013;4:339-344.
3. Mackness M, Boullier A, Hennuyer N, Mackness B, Hall M, Tailleux A, et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun 2000;269:232-236
4. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipo-protein oxidation and preserves its functions. A possible perox-idative role for paraoxonase. J Clin Invest 1998;101:1581-1590.
5. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005;16:393-399.
6. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res 2000;33(Suppl):S85-S97.
7. Mackness M, Mackness B. Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets 2013;17:829-837.
8. Furlong CE, Suzuki SM, Stevens RC, et al. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010;187:355-361.
9. Costa LG, Giordano G, Cole TB, Marsillach J, Furlong CE. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology 2013;307:115-122.
10. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009; 235:1-9.
11. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol 2010;660: 29-35.
12. Ticozzi N, LeClerc AL, Keagle PJ, et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol 2010; 68:102-107.
13. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxication of organo-phosphates and its human polymorphism. Chem Biol Interact 1999;119-120:429-438.
14. Tang WH, Hartiala J, Fan Y, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012;32: 2803-2812.
15. Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraox-onase-1, and HDL form a functional ternary complex. J Clin Invest 2013;123(9):3815-3828.
16. Sand PG. Paraoxonase genes and the susceptibilty to ischemic stroke. Int J Stroke 2013;8:E39.
17. Rothstein L, Jickling GC. Ischemic stroke biomarkers in blood. Biomarkers in Medicine 2013;7:37-47.
18. Yamamoto FI. Ischemic stroke in young adults: an overview of etiological aspects. Arquivos de Neuro-Psiquiatria 2012;70: 462-466.
19. Xing C, Arai K, Lo EH, Hommel M. Pathophysiologic cascades in ischemic stroke. Int J Stroke 2012;7:378-385.
20. Zhang G, Li W, Li Z, et al. Association between paraoxonase gene and stroke in the Han Chinese population. BMC Med Genet 2013;14:16.
21. Liu H, Xia P, Liu M, et al. PON gene polymorphisms and ischaemic stroke: a systematic review and meta analysis. Int J Stroke 2013;8:111-123.
22. Androutsopoulos VP, Kanavouras K, Tsatsakis AM. Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases. Toxicol Appl Pharmacol 2011;256:418-424.
23. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010;23:228-242.
24. Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. Am Fam Phys 2013;87:267-273.
25. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2(8).
26. Selkoe D, Mandelkow E, Holtzman D. Deciphering Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a011460.
27. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2(10).
28. Aharoni S, Aviram M, Fuhrman B. Paraoxonase 1 (PON1) reduces macrophage inflammatory responses. Atherosclerosis 2013;228:353-361.
29. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011;81: 337-344.
30. Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Human Genet 1983;35:393-408.
31. Borowczyk K, Shih DM, Jakubowski H. Metabolism and neu-rotoxicity of homocysteine thiolactone in mice: evidence for a protective role of paraoxonase 1. J Alzheimers Dis 2012;30: 225-231.
32. Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother 2001;55:443-447.
33. Perla-Kajan J, Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J 2010;24: 931-936.
34. Perla-Kajan J, Jakubowski H. Paraoxonase 1 and homocys-teine metabolism. Amino Acids 2012;43:1405-1417.
35. Afriat-Jurnou L, Jackson CJ, Tawfik DS. Reconstructing a missing link in the evolution of a recently diverged phospho-triesterase by active-site loop remodeling. Biochemistry 2012; 51:6047-6055.
36. Bar-Rogovsky H, Hugenmatter A, Tawfik DS. The evolutionary origins of detoxifying enzymes: the mammalian serum para-oxonases (PONs) relate to bacterial homoserine lactonases. J Biol Chem 2013;288(33):23914-23927.
37. Ben-David M, Elias M, Filippi JJ, et al. Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1. J Mol Biol 2012;418:181-196.
38. Draganov D, Teiber J, Watson C, et al. PON1 and oxidative stress in human sepsis and an animal model of sepsis. Adv Exp Med Biol 2010;660:89-97.
39. Draganov DI. Lactonases with organophosphatase activity: structural and evolutionary perspectives. Chem Biol Interact 2010;187:370-372.
40. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-1276.
41. Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv Exp Med Biol 2010;660: 113-127.
42. Mackness B, Mackness MI, Arrol S, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341-349.
43. Kim DS, Burt AA, Ranchalis JE, et al. Additional common polymorphisms in the PON gene cluster predict PON1 activity but not vascular disease. J Lipids 2012;2012:476316.
44. Coplin WM. Critical care management of acute ischemic stroke. Continuum 2012;18:547-559.
45. Perry JM, McCabe KK. Recognition and initial management of acute ischemic stroke. Emerg Med Clin N Am 2012;30: 637-657.
46. Gonzalez RG. Clinical MRI of acute ischemic stroke. J Magnc Reson Imaging 2012;36:259-271.
47. Gross H, Sung G, Weingart SD, Smith WS. Emergency neurological life support: acute ischemic stroke. Neurocritical Care 2012;17(Suppl 1):S29-S36.
48. Yoo AJ, Chaudhry ZA, Leslie-Mazwi TM, et al. Endovascular treatment of acute ischemic stroke: current indications. Tech Vasc Interv Radiol 2012;15:33-40.
49. Schmidt H, Schmidt R, Niederkorn K, et al. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 1998;29:2043-2048.
50. Schmidt R, Schmidt H, Fazekas F, et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the austrian stroke prevention study. Arterioscler Thromb Vasc Biol 2000;20:1811-1816.
51. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxonase 192 Gln->Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002;33:1459-1464.
52. Wang XY, Xue YM, Wen SJ, Zhang NL, Ji Z, Pan SY. The association of paraoxonase 2 gene C311S variant with ischemic stroke in Chinese type 2 diabetes mellitus patients. Chin J Med Genet 2003;20:215-219.
53. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 2004;61:351-356.
54. Ranade K, Kirchgessner TG, Iakoubova OA, et al. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005;36:2346-2350.
55. Aydin M, Gencer M, Cetinkaya Y, et al. PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke. IUBMB Life 2006;58:165-172.
56. Baum L, Ng HK, Woo KS, et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 2006;39:191-195.
57. Pasdar A, Ross-Adams H, Cumming A, et al. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet 2006;7:28.
58. Kim NS, Kang K, Cha MH, et al. Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophys Res Commun 2007;364:157-162.
59. Can Demirdogen B, Turkanoglu A, Bek S, et al. Paraoxonase/ arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 2008;41:1-9.
60. Sarkar PD, Rautaray SS. Oxidized LDL and paraoxanase status in ischemic stroke patients. Indian J Physiol Pharmacol 2008;52:403-407.
61. Shin BS, Oh SY, Kim YS, Kim KW. The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurol Scand 2008;117:237-243.
62. Xu HW, Yuan N, Zhao Z, et al. Study of the relationship between gene polymorphisms of paraoxonase 2 and stroke in a Chinese population. Cerebrovasc Dis 2008;25:87-94.
63. Xiao ZJ, Chen J, Sun Y, Zheng ZJ. Lack of association between the paraoxonase 1 Q/R192 single nucleotide polymorphism and stroke in a Chinese cohort. Acta Neurol Belgica 2009; 109:205-209.
64. Banerjee I. Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis. Eur J Epidemiol 2010;25:449-458.
65. Dahabreh IJ, Kitsios GD, Kent DM, Trikalinos TA. Paraoxonase 1 polymorphisms and ischemic stroke risk: a systematic review and meta-analysis. Genet Med 2010;12: 606-615.
66. Lazaros L, Markoula S, Kyritsis A, Georgiou I. Paraoxonase gene polymorphisms and stroke severity. Eur J Neurol 2010; 17:757-759.
67. Mahrooz A, Gohari G, Hashemi MB, et al. R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke. Mol Biol Reports 2012;39:11177-11785.
68. Michalak S, Kazmierski R, Hellmann A, et al. Serum paraox-onase/arylesterase activity affects outcome in ischemic stroke patients. Cerebrovasc Dis 2011;32:124-132.
69. Shenhar-Tsarfaty S, Waiskopf N, Ofek K, et al. Atherosclerosis and arteriosclerosis parameters in stroke patients associate with paraoxonase polymorphism and esterase activities. Eur J Neurol 2013;20:891-898.
70. Dardiotis E, Xiromerisiou G, Hadjichristodoulou C, Tsatsakis AM, Wilks MF, Hadjigeorgiou GM. The interplay between environmental and genetic factors in Parkinson's disease susceptibility: the evidence for pesticides. Toxicology 2013;307: 17-23.
71. Bohlega SA, Al-Foghom NB. Drug-induced Parkinson's disease. A clinical review. Neurosciences 2013;18:215-221.
72. Park NH. Parkinson disease. J Am Acad Phys Assist 2012;25: 73-74.
73. Kumar KR, Lohmann K, Klein C. Genetics of Parkinson disease and other movement disorders. Curr Opin Neurol 2012;25:466-474.
74. Lee PC, Rhodes SL, Sinsheimer JS, Bronstein J, Ritz B. Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure. Environ Inter 2013;56:42-47.
75. van der Mark M, Brouwer M, Kromhout H, Nijssen P, Huss A, Vermeulen R. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ Health Perspect 2012;120:340-347.
76. Perfeito R, Cunha-Oliveira T, Rego AC. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease - resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med 2012;53:1791-1806.
77. Shi M, Huber BR, Zhang J. Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol 2010;20:660-671.
78. Manthripragada AD, Costello S, Cockburn MG, Bronstein JM, Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010;21:87-94.
79. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009;11:e22.
80. Wu YR. Pesticides and Parkinson's disease. Acta Neurol Taiwan 2005;14:38-39.
81. Fong CS, Cheng CW, Wu RM. Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. Acta Neurol Taiwan 2005;14:55-60.
82. Akhmedova SN, Yakimovsky AK, Schwartz EI. Paraoxonase 1 Met - Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci 2001;184:179-182.
83. Zintzaras E, Hadjigeorgiou GM. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J Human Genet 2004;49:474-481.
84. Clarimon J, Eerola J, Hellstrom O, Tienari PJ, Singleton A. Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. Neurosci Lett 2004;367: 168-170.
85. Kelada SN, Costa-Mallen P, Checkoway H, et al. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:546-547.
86. Carmine A, Buervenich S, Sydow O, Anvret M, Olson L. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov Disord 2002;17:764-766.
87. Taylor MC, Le Couteur DG, Mellick GD, Board PG. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J Neural Transm 2000;107:979-983.
88. Kondo I, Yamamoto M. Genetic polymorphism of paraoxo-nase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res 1998;806:271-3.
89. Liu YL, Yang J, Zheng J, et al. Paraoxonase 1 polymorphisms L55M and Q192R were not risk factors for Parkinson's disease: a HuGE review and meta-analysis. Gene 2012;501:188-192.
90. Belin AC, Ran C, Anvret A, et al. Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease. Neurosci Lett 2012;522:30-35.
91. Wingo TS, Rosen A, Cutler DJ, Lah JJ, Levey AI. Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases. Neurobiol Aging 2012;33:p204 e213-e205.
92. Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 2013;70: 440-444.
93. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012;2:a006346.
94. Masdeu JC, Kreisl WC, Berman KF. The neurobiology of Alzheimer disease defined by neuroimaging. Curr Opin Neurol 2012;25:410-420.
95. Jack CR, Jr. Alzheimer disease: new concepts on its neurobiol-ogy and the clinical role imaging will play. Radiology 2012;263: 344-361.
96. Wehr H, Bednarska-Makaruk M, Graban A, et al. Paraoxonase activity and dementia. J Neurol Sci 2009;283:107-108.
97. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002;252:63-67.
98. Pi Y, Zhang L, Chang K, et al. Lack of an association between Paraoxonase 1 gene polymorphisms (Q192R, L55M) and Alzheimer's disease: a meta-analysis. Neurosci Lett 2012;523: 174-179.
99. Klimkowicz-Mrowiec A, Marona M, Spisak K, et al. Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease. Dement Geriatr Cogn Disord 2011;32:26-31.
100. Chapuis J, Boscher M, Bensemain F, Cottel D, Amouyel P, Lambert JC. Association study of the paraoxonase 1 gene with the risk of developing Alzheimer's disease. Neurobiol Aging 2009;30:152-156.
101. Leduc V, Poirier J. Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neuro-Degenerative Dis 2008;5:225-227.
102. He XM, Zhang ZX, Zhang JW, et al. Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chin Med J 2006;119:1204-1209.
103. Cellini E, Tedde A, Bagnoli S, et al. Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neurosci Lett 2006;408:199-202.
104. Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann N Y Acad Sci 2002;977:239-244.
105. Zuliani G, Ble A, Zanca R, et al. Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia. Acta Neurol Scand 2001;103:304-308.
106. D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013;65C:509-527.
107. Evans MC, Couch Y, Sibson N, Turner MR. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013;53:34-41.
108. Kruger D. Amyotrophic lateral sclerosis. JAAPA 2012;25:53-54.
109. Ludolph AC, Brettschneider J, Weishaupt JH. Amyotrophic lateral sclerosis. Curr Opin Neurol 2012;25:530-535.
110. Gagliardi S, Abel K, Bianchi M, et al. Regulation of FMO and PON detoxication systems in ALS human tissues. Neurotoxicity Res 2013;23:370-377.
111. Cronin S, Greenway MJ, Prehn JH, Hardiman O. Paraoxonase promoter and intronic variants modify risk of sporadic amyo-trophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007; 78:984-986.
112. Wills AM, Cronin S, Slowik A, et al. A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology 2009;73:16-24.
113. Wills AM, Landers JE, Zhang H, et al. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology 2008;70:929-934.
114. Freedman MS. Present and emerging therapies for multiple sclerosis. Continuum 2013;19:968-991.
115. Katz Sand IB, Lublin FD. Diagnosis and differential diagnosis of multiple sclerosis. Continuum 2013;19:922-943.
116. Miller E, Wachowicz B, Majsterek I. Advances in antioxidative therapy of multiple sclerosis. Curr Med Chem 2013.
117. Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum 2013;19: 901-921.
118. Martinez C, Garcia-Martin E, Benito-Leon J, et al. Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis. Neuromol Med 2010;12:217-223.
119. Moghtaderi A, Hashemi M, Sharafaddinzadeh N, et al. Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: a case-control study. Clin Biochem 2011;44:795-798.
120. Sidoti A, Antognelli C, Rinaldi C, et al. Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Mult Scler 2007;13: 446-453.
121. Zakrzewska-Pniewska B, Nojszewska M, Rog T, et al. Polymorphisms of paraoxonase 1 and 2 genes and the risk of multiple sclerosis in the Polish population. Neurologia i neuro-chirurgia polska 2013;47:49-52.
122. Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H. Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 2009;15:399-402.